Abstract:TPS491 Background: Combination immune checkpoint inhibition (ICI) with ipilimumab and nivolumab (ipi/nivo) is an established first-line treatment for patients (pts) with intermediate and poor-risk mRCC. CheckMate214 demonstrated a survival advantage with ipi/nivo over sunitinib; unfortunately, 20% of cases developed primary progression to immunotherapy. Recent data suggest that the gut microbiome is key in modulating clinical responses and immune-related toxicities. Therefore, modulating the gut microbiome is a novel adjunct strategy to dual ICI in mRCC. Our group has previously proven that the addition of a live bacterial product (CBM588) enhances clinical responses in pts with mRCC treated with ICI, and the combination of ICI (Dizman et al., 2022) or with a tyrosine kinase inhibitor (Ebrahimi et al., 2023). Camu camu ( Myrciaria dubia) is a comestible berry characterized by a polyphenol-rich nutritional profile. In extract form, it is rich in castalagin, which appears to have probiotic properties. In mouse tumor models, camu camu increased the abundance of fecal Ruminococcus spp. when combined with ICI (Messaoudene et al., 2022). This shift in the gut microbiome composition was associated with stronger CD8+ T-cell and CD4+ Th1-dependent antitumor responses. Camu camu and ICI reestablished the efficacy of anti-PD1 therapy, reducing tumor size compared to ICI alone. This pilot study aims to identify the biological effect of camu camu with ipi/nivo in pts with mRCC. Methods: This is an investigator-initiated, randomized, open-label, single-center trial comparing camu camu with ipi/nivo versus ipi/nivo alone in pts with treatment-naïve mRCC. Eligibility criteria include pts ≥ 18 year old, PS 0-1, histological confirmation of clear-cell RCC with or without a sarcomatoid component, intermediate or poor risk per IMDC, no prior systemic treatment and measurable disease,. 30 pts will be enrolled and randomized in a 2:1 fashion, favoring the study arm. Pts will be treated with camu camu at 1500 mg PO daily, in with ipi/nivo at standard dosing. Pts will be followed monthly. Treatment will be continued until progression (RECIST v1.1) or toxicity. The primary endpoint is change in the abundance of Ruminococcus spp. in the stool from baseline to week 12 of therapy. We have 80% power to detect a 1 SD difference between the mean change detected in the two groups using a two-group T-test with a one-sided type I error of 0.05. Secondary endpoints include overall response rate, progression-free survival, safety, effect on gut microbiome diversity and function, comparison of the proportion of circulating cytokines and chemokines from baseline to week 12, and changes in the abundance of metabolic pathways and fungal microbiome profile. Response will be assessed by CT after the first 12 weeks of therapy and every 12 weeks, thereafter. The study is currently open to enrollment. Clinical trial information: NCT06049576 .

Camu Camu effects on microbial translocation and systemic immune activation in ART-treated people living with HIV: protocol of the single-arm non-randomised Camu Camu prebiotic pilot study (CIHR/CTN PT032)

Increased Microbial Translocation is a Prognostic Biomarker of Different Immune Responses to ART in People Living with HIV

Randomized pilot trial of a synbiotic dietary supplement in chronic HIV-1 infection

Specific prebiotics modulate gut microbiota and immune activation in HAART-naive HIV-infected adults: results of the “COPA” pilot randomized trial

Effects of Immunonutrition in Advanced Human Immunodeficiency Virus Disease: A Randomized Placebo-controlled Clinical Trial (Promaltia Study)

Camu-camu decreases hepatic steatosis and liver injury markers in overweight, hypertriglyceridemic individuals: A randomized crossover trial

CTNPT 028

Prospective Correlation Between the Patient Microbiome with Response to and Development of Immune-Mediated Adverse Effects to Immunotherapy in Lung Cancer.

Fecal microbiota transplantation alters the proteomic landscape of inflammation in HIV: identifying bacterial drivers

Understanding and optimizing brain health in HIV now: protocol for a longitudinal cohort study with multiple randomized controlled trials

Novel Immunological Markers of Intestinal Impairment Indicative of HIV-1 Status and/or Subclinical Atherosclerosis

Trans cohort metabolic reprogramming towards glutaminolysis in long-term successfully treated HIV-infection

Two Cases of Durable and Deep Responses to Immune Checkpoint Inhibition-Refractory Metastatic Melanoma after Addition of Camu Camu Prebiotic

The Potential of Clostridium butyricum to Preserve Gut Health, and to Mitigate Non-AIDS Comorbidities in People Living with HIV

Combination nivolumab and ipilimumab with and without camu camu in first-line treatment of metastatic renal cell carcinoma (mRCC).

Targeting the Gut Microbiota of Vertically HIV-Infected Children to Decrease Inflammation and Immunoactivation: A Pilot Clinical Trial

Synbiotic therapy decreases microbial translocation and inflammation and improves immunological status in HIV-infected patients: a double-blind randomized controlled pilot trial

Influence of dietary supplementation of short-chain fatty acid sodium propionate in people living with HIV (PLHIV)

Lights and Shadows of Microbiota Modulation and Cardiovascular Risk in HIV Patients

Therapeutic microbiome modulation: new frontiers in HIV treatment

Preliminary Effects of an Urban Gardens and Peer Nutritional Counseling Intervention on HIV Treatment Adherence and Detectable Viral Load Among People with HIV and Food Insecurity: Evidence from a Pilot Cluster Randomized Controlled Trial in the Dominican Republic